EIP PHARMA, LLC logo

EIP PHARMA, LLC

EIP Pharma, LLC is a pharma company developing therapeutic for the treatment of neuroinflammation and dysfunction of microglia and the major immune-cell in the brain.

In 2012, EIP Pharma in-licensed VX-745 from Vertex Pharmaceuticals Inc. Vertex in association with Kissei Pharmaceutical Co Ltd, is developing VX-745, for the potential treatment of rheumatoid arthritis (RA).

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.eippharma.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
210 Broadway, Suite 201,MA 2139
Cambridge
United States
Email
Contact Number
+1 617 8633751

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/eip-pharma-llc” connections=”true” suffix=””]

EIPs collaboration with laboratory of Prof. Ralph A. Nixon of NYU Langone MC and the Nathan Kline Institute for Psychiatric Research, evaluated effects of in-vitro VX-745 treatment of Down syndome fibroblasts on Amyloid Precursor Protein induced endosomal-lysosomal dysfunction, which showed endosomal abnormalities in DS-fibroblasts reversing with 1,10 or 50 nM neflamapimod. Its potency estimated to be 5 fold lower than the potency of VX-745 on episodic memory.

In May 2018, EIP pharma received $20.5Mn in Series B financing led by Access Industries. Proceeds from the financing will be used to further advance development of neflamapimod (previously VX-745).